Methods of treating metabolic disorders associated with lipodystrophy and a deficiency in insulin production or deficiency in insulin signaling

摘要

The present invention relates to FGF21 polypeptides or FGF21 proteins, or mutants, variants, and fusions thereof, such as metabolic diseases associated with a deficiency in insulin signaling (eg, insulin receptor mutation disorder (INSR)). Disorders) and / or autoimmune insulin receptor disorders (type B insulin resistance)), metabolism associated with deficiency in insulin production, such as type 1 diabetes, mixed dyslipidemia, nonalcoholic fatty liver disease (NAFLD) Of new therapies to treat various lipodystrophy, including sexually transmitted diseases and other metabolic disorders, and HIV / HAART-induced partial lipodystrophy, to reduce mortality and morbidity in critically ill patients Regarding identification.